Embody received US $3.6MM led by the cultivate(MD) Capital Fund II. The infusion will support pre-launch and pre-commercial activities for the Tapestry collagen-based microfiber implant, used in Achilles tendon and rotator cuff repairs.
Tapestry’s design is based on research of collagen increasing the activity of recellularization by growing new aligned tissue over surgical repairs. Studies will seek to prove that scarring is minimized, and post-op rehabilitation accelerated.
Last year, Embody received $12.1MM in DARPA funding and an R&D contract, which funded product development.
cultivate(MD), a fund under the Genesis Innovation Group, invests in early-stage healthcare companies and focuses especially on medical device and orthopedic technologies that have demonstrated evidence of effectiveness.
Source: cultivate(MD); ORTHOWORLD Inc.
Embody received US $3.6MM led by the cultivate(MD) Capital Fund II. The infusion will support pre-launch and pre-commercial activities for the Tapestry collagen-based microfiber implant, used in Achilles tendon and rotator cuff repairs.
Tapestry's design is based on research of collagen increasing the activity of recellularization by growing...
Embody received US $3.6MM led by the cultivate(MD) Capital Fund II. The infusion will support pre-launch and pre-commercial activities for the Tapestry collagen-based microfiber implant, used in Achilles tendon and rotator cuff repairs.
Tapestry’s design is based on research of collagen increasing the activity of recellularization by growing new aligned tissue over surgical repairs. Studies will seek to prove that scarring is minimized, and post-op rehabilitation accelerated.
Last year, Embody received $12.1MM in DARPA funding and an R&D contract, which funded product development.
cultivate(MD), a fund under the Genesis Innovation Group, invests in early-stage healthcare companies and focuses especially on medical device and orthopedic technologies that have demonstrated evidence of effectiveness.
Source: cultivate(MD); ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





